Compare Gilead Sciences, Inc. (GILD) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs T Rowe Price Group Inc — how do they compare? Gilead Sciences, Inc. trades at $133.72 (market cap $163.51B), while T Rowe Price Group Inc trades at $119.35 (market cap $25.41B). The key difference: Gilead Sciences, Inc. is far larger — about 6.4× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.39%). Which is the better fit depends on your goals.
| GILD | TROW | |
|---|---|---|
Market Cap | $163.51B | $25.41B |
Sector | Health | Financials |
52-Week High | $155.80 | $120.16 |
52-Week Low | $108.22 | $86.19 |
Enterprise Value | $178.05B | $22.12B |
Dividend Yield | 2.49% | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
T. Rowe Price (TROW) trades at $116.07, up 2.13% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 12.72, net income margin of 28.28%, and consistent earnings beats. Recent AUM growth to $1.89 trillion and strategic institutional enhancements support positive momentum. Technical indicators show the stock trading near pivot point resistance at $116 with support at $115.
TROW presents a compelling value opportunity with attractive valuation metrics and strong profitability. The primary risk remains equity outflows despite diversification efforts. Analyst consensus is cautious with 63% hold ratings, though recent Zacks upgrades to Strong Buy highlight growing optimism. The stock's current price sits above the consensus target of $109.17, suggesting limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
